| For: | Kamrul-Hasan ABM, Pappachan JM, Dutta D, Nagendra L, Kuchay MS, Kapoor N. Reasons for discontinuing tirzepatide in randomized controlled trials: A systematic review and meta-analysis. World J Diabetes 2025; 16(4): 101731 [PMID: 40236848 DOI: 10.4239/wjd.v16.i4.101731] |
|---|---|
| URL: | https://www.wjgnet.com/1948-9358/full/v16/i4/101731.htm |
| Number | Citing Articles |
| 1 |
J.L. Sievenpiper, J. Ard, M. Blüher, W. Chen, J.B. Dixon, A. Fitch, L. Gigliotti, K. Khunti, A. Lecube, M.E.J. Lean, B. Mittendorfer, A.F.H. Pfeiffer, D.H. Ryan, T. Vilsbøll, L.F. Van Gaal. Nutritional and lifestyle supportive care recommendations for management of obesity with GLP-1 - based therapies: An expert consensus statement using a modified Delphi approach. Obesity Pillars 2026; 17 doi: 10.1016/j.obpill.2025.100228
|
| 2 |
Jairo A. Noreña, Tugce Akcan, Dimpi Desai. Beyond weight loss: tirzepatide as a dual GIP/GLP-1 receptor agonist for obstructive sleep apnea. Current Opinion in Endocrinology, Diabetes & Obesity 2026; 33(3) doi: 10.1097/MED.0000000000000949
|
| 3 |
Krzysztof Łupina, Artur Dziewierz, Jakub Janczura, Zbigniew Siudak. Switching patterns of GLP-1 receptor agonists from 2018 to 2025 in the largest private healthcare network in Poland. Acta Diabetologica 2026; doi: 10.1007/s00592-026-02709-1
|
| 4 |
Henry D. Heisey, L. Parker Gregg, Christopher D. Verrico, Dennis T. Villareal, Terri L. Fletcher. Rates of, Reasons for, and Reactions to Discontinuation of GLP‐1 Receptor Agonists: A Narrative Review. Diabetes, Obesity and Metabolism 2026; doi: 10.1111/dom.70913
|